Jasper’s Expanding Pipeline

Jasper maintains worldwide rights to develop and commercialize Briquilimab and Jasper mRNA Stem Cell Grafts in all indications.

 

Product
RESEARCH
PRECLINICAL
CLINICAL
R&D PARTNER
Briquilimab (JSP191)
Therapeutic Development
    Chronic Urticaria
    Low to Intermediate Risk MDS Therapeutic
Transplant Development
    SCID
    AML/MDS
    Fanconi Anemia
Partner
    Sickle Cell Disease
Partner
    CGD
Partner
    GATA2 MDS
Partner
Jasper mRNA Stem Cell Graft Platform
    Thalassemias, Sickle Cell Disease
    Autoimmune Diseases

MDS: Myelodysplastic Syndrome
SCID: Severe Combined Immunodeficiency
AML: Acute Myeloid Leukemia
CGD: Chronic Granulomatous Disease
GATA2 MDS: MDS with germline GATA2 mutations

 
 
EXPANDED ACCESS

Jasper is a clinical stage biotechnology company focused on the development of novel curative therapies by focusing on the biology of the hematopoietic stem cell. Jasper’s lead program, Briquilimab, is an investigational therapy currently being studied in multiple clinical trials for serious and life-threatening conditions. Participation in a clinical trial of Briquilimab is the best way to access Briquilimab investigational therapy. Jasper does not currently provide access to our investigational therapies under Expanded Access.

 

 

Top